Research paperEB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro
References (43)
- et al.
Human colon cell line HT-29. Characterisation of 1,25-dihydroxyvitamin D3 receptor and induction of differentiation by the hormone
J Steroid Biochem
(1988) - et al.
Possible role for vitamin D in controlling breast cancer cell proliferation
Lancet
(1989) - et al.
Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton. A trial of the development of vitamin D compounds which exhibit potent differentiation-inducing activity without inducing hypercalcemia
FEBS Lett
(1987) - et al.
Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo
Biochem Pharmacol
(1988) - et al.
Double blind right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris
Lancet
(1991) - et al.
Topical calcipotriol treatment in advanced breast cancer
Lancet
(1991) - et al.
Effects of synthetic Vitamin D analogues on breast cancer cell proliferation in vivo and in vitro
Biochem Pharmacol
(1992) - et al.
Growth factors in bone matrix
J Biol Chem
(1986) - et al.
Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs
J Biol Chem
(1987) - et al.
Biological activity of 24,24 difluoro-1α,25-dihydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3-26,23-lactone in inducing differentiation of human myeloid leukemia cells
Arch Biochem Biophys
(1983)
20-Epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses
Biochem Pharmacol
Molecular biology of the vitamin D hormone
Recent Prog Hormone Res
Chicken intestinal receptor for 1,25-dihydroxyvitamin D3. Immunologic characterization and homogeneous isolation of a 60,000-dalton protein
J Biol Chem
The role of the vitamin D endocrine system in health and disease
N Engl J Med
Differentiation of mouse myeloid leukemia cells induced by 1,25-dihydroxyvitamin D3
Induction of monocytic differentiation and bone resorption by 1,25-dihydroxyvitamin D3
Differentiation of a human monocytic cell line by 1,25 dihydroxyvitamin D3 (calcitriol). A morphologic phenotype and functional analysis
Blood
1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of growth in culture
Endocrinology
Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites
Cancer Res
Regulation of terminal differentiation of cultured mouse epidermal cells by 1α,25-dihydroxyvitamin D3
Endocrinology
Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells
Cancer Res
Cited by (236)
Overview of vitamin D actions in cancer
2023, Feldman and Pike's Vitamin D: Volume Two: Disease and TherapeuticsThe role of vitamin D in cancer prevention
2015, Chinese Journal of Natural MedicinesSuppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D<inf>3</inf> and its receptor
2015, Journal of Steroid Biochemistry and Molecular BiologyCitation Excerpt :Elucidation of the molecular mechanism underlying the suppression of EOC invasion mediated through stromal VDR relies on the identification of the main cell types in omental tumor microenvironment that mediate the 1,25D3 action through the stromal VDR. EB1089 is a 1,25D3 analog that is less calcemic than 1,25D3, but more potent than the natural VDR ligand in suppressing the growth of prostate [2,4,25,29], breast [8], colon [1,22] and retinoblastoma [31] tumors. Despite the promise of EB1089 shown in pre-clinical studies, attempts to translate these results to therapy in the clinics for other cancers have been disappointing to date.
Vitamin D analog EB1089 inhibits aromatase expression by dissociation of comodulator WSTF from the CYP19A1 promoter-a new regulatory pathway for aromatase
2013, Biochimica et Biophysica Acta - Molecular Cell ResearchCitation Excerpt :Furthermore, different animal studies have shown that EB1089 is able to reduce mammary tumor progression in vivo in rats [17–19] and mice [20–24] and it has also been reported that treatment with EB1089 increased the survival time and inhibited bone metastases in mice [20]. In rat, the effect of EB1089 was found to be superior to the effect of 1α,25-dihydroxyvitamin D3 [17]. EB1089 has undergone clinical phase I and II trials and was found to be a well tolerated compound [25].
TEI-A00114: A new vitamin D<inf>3</inf> analogue that inhibits neutrophil recruitment in an acute lung injury hamster model while showing reduced hypercalcemic activity
2012, SteroidsCitation Excerpt :Providing vitamin D3 analogues with a lower affinity for DBP is one approach for addressing the hypercalcemic effect. In fact, some vitamin D3 analogues which exhibit dissociated biological profiles have a lower binding affinity for DBP [4,5,7,31,32]. In addition, several vitamin D3 analogues with dissociated biological profiles that are tissue-selective and cell context-dependent have been developed [33,34].